OncoMatch/Clinical Trials/NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Is NCT06043323 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Axicabtagene Ciloleucel and Cyclophosphamide for follicular lymphoma.
Treatment: Axicabtagene Ciloleucel · Cyclophosphamide · Fludarabine phosphate · Prednisone · Diphenhydramine · Acetaminophen — To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
hemoglobin level ≥ 8 g/dl
Kidney function
crcl ≥ 45 ml/min/m2
Liver function
alt/ast ≤ 2.5 × uln or ≤ 5 x uln if documented liver involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06043323 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages